Ming Sun1, Craig S Pace, Xin Yao, Faye Yu, Neal N Padte, Yaoxing Huang, Michael S Seaman, Qihan Li, David D Ho. 1. *Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY; †Institute of Medical Biology, Chinese Academy of Medical Science and Peking Union Medical College, Kunming, China; and ‡Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Although broadly neutralizing monoclonal antibodies (bNAbs) have always been considered to be a potential therapeutic option for the prophylaxis and treatment of HIV infection, their lack of breadth against all HIV variants has been one of the limiting factors. To provide sufficient neutralization breadth and potency against diverse viruses, including neutralization escape mutants, strategies to combine different bNAbs have been explored recently. METHODS: We rationally designed and engineered a novel bispecific HIV-1-neutralizing antibody (bibNAb), iMabm36. The potency and breadth of iMabm36 against HIV were extensively characterized in vitro. RESULTS: iMabm36 comprises the anti-CD4 Ab ibalizumab (iMab) linked to 2 copies of the single-domain Ab m36, which targets a highly conserved CD4-induced epitope. iMabm36 neutralizes a majority of a large, multiclade panel of pseudoviruses (96%, n = 118) at an IC50 concentration of less than 10 µg/mL, with 83% neutralized at an IC50 concentration of less than 0.1 µg/mL. In addition, iMabm36 neutralizes a small panel of replication-competent transmitted-founder viruses to 100% inhibition at a concentration of less than 0.1 µg/mL in a peripheral blood mononuclear cell-based neutralizing assay. Mechanistically, the improved antiviral activity of iMabm36 is dependent on both the CD4-binding activity of the iMab component and the CD4i-binding activity of the m36 component. After characterizing that viral resistance to iMabm36 neutralization was due to mutations residing in the bridging sheet of gp120, an optimized m36 variant was engineered that, when fused to iMab, improved antiviral activity significantly. CONCLUSIONS: The interdependency of this dual mechanism of action enables iMabm36 to potently inhibit HIV-1 entry. These results demonstrate that mechanistic-based design of bibNAbs can generate potential preventive and therapeutic candidates for HIV/AIDS.
BACKGROUND: Although broadly neutralizing monoclonal antibodies (bNAbs) have always been considered to be a potential therapeutic option for the prophylaxis and treatment of HIV infection, their lack of breadth against all HIV variants has been one of the limiting factors. To provide sufficient neutralization breadth and potency against diverse viruses, including neutralization escape mutants, strategies to combine different bNAbs have been explored recently. METHODS: We rationally designed and engineered a novel bispecific HIV-1-neutralizing antibody (bibNAb), iMabm36. The potency and breadth of iMabm36 against HIV were extensively characterized in vitro. RESULTS: iMabm36 comprises the anti-CD4 Ab ibalizumab (iMab) linked to 2 copies of the single-domain Ab m36, which targets a highly conserved CD4-induced epitope. iMabm36 neutralizes a majority of a large, multiclade panel of pseudoviruses (96%, n = 118) at an IC50 concentration of less than 10 µg/mL, with 83% neutralized at an IC50 concentration of less than 0.1 µg/mL. In addition, iMabm36 neutralizes a small panel of replication-competent transmitted-founder viruses to 100% inhibition at a concentration of less than 0.1 µg/mL in a peripheral blood mononuclear cell-based neutralizing assay. Mechanistically, the improved antiviral activity of iMabm36 is dependent on both the CD4-binding activity of the iMab component and the CD4i-binding activity of the m36 component. After characterizing that viral resistance to iMabm36 neutralization was due to mutations residing in the bridging sheet of gp120, an optimized m36 variant was engineered that, when fused to iMab, improved antiviral activity significantly. CONCLUSIONS: The interdependency of this dual mechanism of action enables iMabm36 to potently inhibit HIV-1 entry. These results demonstrate that mechanistic-based design of bibNAbs can generate potential preventive and therapeutic candidates for HIV/AIDS.
Authors: Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson Journal: AIDS Res Hum Retroviruses Date: 2002-11-01 Impact factor: 2.205
Authors: Shi-Hua Xiang; Liping Wang; Mariam Abreu; Chih-Chin Huang; Peter D Kwong; Eric Rosenberg; James E Robinson; Joseph Sodroski Journal: Virology Date: 2003-10-10 Impact factor: 3.616
Authors: Christine Armbruster; Gabriela M Stiegler; Brigitta A Vcelar; Walter Jäger; Nelson L Michael; Norbert Vetter; Hermann W D Katinger Journal: AIDS Date: 2002-01-25 Impact factor: 4.177
Authors: A Trkola; T J Ketas; K A Nagashima; L Zhao; T Cilliers; L Morris; J P Moore; P J Maddon; W C Olson Journal: J Virol Date: 2001-01 Impact factor: 5.103
Authors: Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton Journal: J Virol Date: 2003-10 Impact factor: 5.103
Authors: Daniel R Kuritzkes; Jeffrey Jacobson; William G Powderly; Eliot Godofsky; Edwin DeJesus; Frances Haas; Keith A Reimann; Jeffrey L Larson; Patrice O Yarbough; Valentin Curt; William R Shanahan Journal: J Infect Dis Date: 2004-01-08 Impact factor: 5.226
Authors: Hyeryun Choe; Wenhui Li; Paulette L Wright; Natalya Vasilieva; Miro Venturi; Chih-Chin Huang; Christoph Grundner; Tatyana Dorfman; Michael B Zwick; Liping Wang; Eric S Rosenberg; Peter D Kwong; Dennis R Burton; James E Robinson; Joseph G Sodroski; Michael Farzan Journal: Cell Date: 2003-07-25 Impact factor: 41.582
Authors: Flavia Ferrantelli; Regina Hofmann-Lehmann; Robert A Rasmussen; Tao Wang; Weidong Xu; Pei-Lin Li; David C Montefiori; Lisa A Cavacini; Hermann Katinger; Gabriela Stiegler; Daniel C Anderson; Harold M McClure; Ruth M Ruprecht Journal: AIDS Date: 2003-02-14 Impact factor: 4.177
Authors: David Wensel; Yongnian Sun; Zhufang Li; Sharon Zhang; Caryn Picarillo; Thomas McDonagh; David Fabrizio; Mark Cockett; Mark Krystal; Jonathan Davis Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191
Authors: Mario V Beccari; Bryan T Mogle; Eric F Sidman; Keri A Mastro; Elizabeth Asiago-Reddy; Wesley D Kufel Journal: Antimicrob Agents Chemother Date: 2019-05-24 Impact factor: 5.191
Authors: Ruijiang Song; Craig Pace; Michael S Seaman; Qing Fang; Ming Sun; Chasity D Andrews; Amos Wu; Neal N Padte; David D Ho Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: M Asokan; R S Rudicell; M Louder; K McKee; S O'Dell; G Stewart-Jones; K Wang; L Xu; X Chen; M Choe; G Chuang; I S Georgiev; M G Joyce; T Kirys; S Ko; A Pegu; W Shi; J P Todd; Z Yang; R T Bailer; S Rao; P D Kwong; G J Nabel; J R Mascola Journal: J Virol Date: 2015-10-07 Impact factor: 5.103